Drug Trial Radar · NCT03683251
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Sep 20, 2018
Primary completion
Dec 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 25, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
Conditions
- Neovascular Age-Related Macular Degeneration
Interventions
PDS Implant with Ranibizumab 100 mg/mLDrug
Will be administered as per the schedule described in individual arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Ocular and Systemic (Non-Ocular) Adverse Events (AEs)Time frame: Baseline up to Week 240
- Incidence, Severity, and Duration of Adverse Event of Special Interest (AESIs)Time frame: Baseline up to Week 240
- Incidence, Severity, and Duration of PDS-Associated Ocular AESIs During the Postoperative Period (Up to 37 days of Initial Implantation) and Follow-Up Period (>37 days After Implantation Surgery) for Participants who Receive the PDS Implant in the StudyTime frame: Baseline up to Week 240
- Incidence and Severity of Adverse Device EffectsTime frame: Baseline up to Week 240
- Incidence, Causality, Severity, And Duration Of Anticipated Serious Adverse Device EffectsTime frame: Baseline up to Week 240
- Sub-study 1: Rate of Vitreous Hemorrhage Secondary to Choroidal Bleeding That Does not Resolve by the Week 4 Visit After Implant Insertion Surgery.Time frame: Baseline to Week 4
- Sub-study 2: Number of Participants with Ocular and Systemic (Non-ocular) Adverse Events (AEs) and Severity of These AEsTime frame: Baseline to Week 72
- Sub-study 2: Number of Participants with Adverse Events of Special Interests (AESIs) and Severity of AESIsTime frame: Baseline to Week 72
- Sub-study 2: Duration of AESIsTime frame: Baseline to Week 72
- Sub-study 2: Number of participants with Ocular AESIs and Severity of Ocular AESIs During the Post-operative PeriodTime frame: Up to Day 37 post re-implantation
- Sub-study 2: Number of participants with Ocular AESIs and Severity of Ocular AESIs During the Follow-up PeriodTime frame: > 37 days post re-implantation (up to approximately Week 72)
- Sub-study 2: Duration of Ocular AESIs During the Post-operative PeriodTime frame: Up to Day 37 post re-implantation
- Sub-study 2: Duration of Ocular AESIs During the Follow-up PeriodTime frame: > 37 days post re-implantation (up to approximately Week 72)
- Sub-study 2: Number of Participants with Adverse Device Effects (ADEs) and Severity of ADEsTime frame: Baseline to Week 72
- Sub-study 2: Number of Participants with Anticipated Serious ADEs and Severity of Anticipated Serious ADEsTime frame: Baseline to Week 72
- Sub-study 2: Duration of Anticipated Serious ADEsTime frame: Baseline to Week 72
- Sub-study 2: Number of Device DeficienciesTime frame: Baseline to Week 72
Locations
165 sites in 15 countries. Site status is shown where the registry gives one.
Retinal Research Institute, LLC
Phoenix, Arizona · Completed
Arizona Retina and Vitreous Consultants
Phoenix, Arizona · Completed
Barnet Dulaney Perkins Eye Center
Phoenix, Arizona · Active not recruiting
Associated Retina Consultants
Phoenix, Arizona · Completed
Retinal Consultants of Arizona
Phoenix, Arizona · Completed
California Retina Consultants
Bakersfield, California · Completed
Retina-Vitreous Associates Medical Group
Beverly Hills, California · Completed
The Retina Partners
Encino, California · Active not recruiting
Jacobs Retina center at the Shiley eye Institute UCSD
La Jolla, California · Completed
Jules Stein Eye Institute/ UCLA
Los Angeles, California · Completed
N CA Retina Vitreous Assoc
Mountain View, California · Completed
Retina Consultants, San Diego
Poway, California · Completed
Retinal Consultants Med Group
Sacramento, California · Completed
West Coast Retina Medical Group
San Francisco, California · Completed
UCSF
San Francisco, California · Completed
Orange County Retina Med Group
Santa Ana, California · Active not recruiting
California Retina Consultants
Santa Barbara, California · Completed
Southwest Retina Consultants
Durango, Colorado · Completed
Eye Center of Northern CO
Fort Collins, Colorado · Completed
Colorado Retina Associates, PC
Lakewood, Colorado · Completed
Retina Group of New England
Waterford, Connecticut · Completed
Florida Eye Microsurgical Inst
Boynton Beach, Florida · Completed
National Ophthalmic Research Institute
Fort Myers, Florida · Completed
Florida Eye Associates
Melbourne, Florida · Completed
Retina Care Specialists
Palm Beach Gardens, Florida · Completed
Retina Specialty Institute
Pensacola, Florida · Completed
Fort Lauderdale Eye Institute
Plantation, Florida · Completed
Retina Vitreous Assoc of FL
St. Petersburg, Florida · Active not recruiting
Southern Vitreoretinal Assoc
Tallahassee, Florida · Active not recruiting
Retina Associates of Florida, LLC
Tampa, Florida · Completed
Southeast Retina Center
Augusta, Georgia · Completed
Georgia Retina PC
Marietta, Georgia · Withdrawn
Illinois Retina Associates
Joliet, Illinois · Completed
University Retina and Macula Associates, PC
Oak Forest, Illinois · Completed
Wolfe Eye Clinic
West Des Moines, Iowa · Completed
Retina Associates
Lenexa, Kansas · Completed
Retina Associates of Kentucky
Lexington, Kentucky · Completed
Paducah Retinal Center
Paducah, Kentucky · Withdrawn
Maine Eye Center
Portland, Maine · Completed
The Retina Care Center
Baltimore, Maryland · Completed
Showing 40 of 165 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.